A small focused company, like Day One, can execute rapidly to deliver new treatments for people with cancer. "This confluence allows new targeted therapies to be developed for both childhood and adult cancers with equal speed and intensity. In parallel, Day One leverages improvements in pediatric oncology clinical trial infrastructure and modern study designs to execute faster and more efficient clinical trials for children with cancer. "Our goal is to dramatically change the pace of new cancer drug development for children by identifying and developing novel therapies based on pediatric cancer biology, and then following the biology to the benefit of all patients whether they are children or adults." Enabled by advances in the understanding of the biology of childhood cancers, and informed by its network of leading pediatric oncologists, Day One is equipped to identify patients across the age spectrum who are likely to benefit from a new treatment based upon their tumor's biology. Samuel Blackman, co-founder, pediatric oncologist, and Chief Medical Officer of Day One. As a result, only 10 new drugs for pediatric cancer have been FDA approved over the last 30 years," explained Dr. This disparity in access occurs for multiple reasons, including the prioritization of adult cancers that can create larger markets a development model that remains centered on adult conditions versus mechanism of action and outdated assumptions around trial feasibility in pediatric oncology. "In the US, children with cancer first gain access to cutting-edge investigational treatments an average of 6.5 years later than adults. Yet, children with cancer continue to be left behind. Advances in cancer research enable drug developers to identify children and adults who may benefit from the same medicine. Today, Day One unveils its team, $60M Series A financing, and announces its first promising clinical-stage oncology treatment, which Day One acquired through Takeda Pharmaceutical Company Limited. Using new insights from the biology of pediatric cancer, Day One Biopharmaceuticals develops promising new oncology therapies that change outcomes for people of all ages.
0 Comments
Leave a Reply. |